[On the problem of medicamentous therapy of chronic polypous rhinosinusitis].
Chronic polypous rhinosinusitis (CPS) is currently regarded as a condition requiring medicamentous therapy rather than surgical treatment at the early stages. The choice of therapeutic modalities depends on pathogenetic mechanisms underlying formation of polyps. The International Consensus Conference on Nasal Polyposis (2006) and European documents EAACI - EP3OS (2007) recommend topical (endonasal) glucocorticoids, systemic antibiotics (long-term treatment with low doses of macrolides), antimycotic preparations, and other pharmaceuticals as the main medicinal products for the management of polypous rhinosinusitis (PR). Based on the concept of CPS as an immune-dependent condition, the authors developed the rationale for the use of immunomodulators in combination with etiotropic drugs (antiviral, antibacterial, and antimycotic) for the management of this disease. Advantages of Imunofan application (both local and systemic) during surgical intervention for the treatment of nasal polyps are discussed. It is concluded that combined medicamentous treatment restricts the growth and recurrence of nasal polyps.